"Bayer Pharmaceuticals has announced advancements in its growth strategy and pipeline at its annual Pharma Media Day. As part of the ongoing transformation of its pharmaceutical business, the company has made investments in R&D to accelerate medical innovations.
The objective is to build a differentiated pipeline for long-term growth across key therapeutic areas, including oncology, cardiovascular diseases, neurology and rare diseases, and immunology. It is also making significant progress with its cell and gene therapy platform, especially in the field of Parkinson’s disease, said the company.
“2025 is a landmark launch year for Bayer Pharmaceuticals, and we are pulling out all stops to drive the power of our pipeline. “Our growth strategy is on track and delivering significant value. This year, we are bringing a number of groundbreaking products with blockbuster potential to market,” said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division.
Through rigorous assessment and prioritization, the company plans to offer a number of new treatment options by expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe. Besides an innovative hormone-free treatment to relieve moderate to severe vasomotor symptoms in menopausal women and metastatic hormone-sensitive prostate cancer, further building Bayer’s leadership position in this field, said the company in its note.
""We are shaping a new era of medicine, confident that we can not only transform patient care through breakthrough innovation and a robust product portfolio, but also by accelerating patient access to new medicines. With every new development, we are getting one step closer to realizing our vision to treat the untreatable, cure disease and offer hope,” said Christine Roth, executive vice president, global product strategy and commercialization and member of the pharmaceuticals leadership team at Bayer.
Dr Christian Rommel, member of the executive committee, Bayer’s Pharmaceuticals Division and head of research and development said, Our renewed early pipeline positions us for long-term growth and allows us to progress targeted treatments that promise to significantly improve patient outcomes. Now, we are poised to deliver innovative therapies that will make a meaningful difference in patients' lives while driving sustainable business growth.”
Driving progress throughout its oncology pipeline, which spans all phases of clinical development, Bayer is building on its goal to become a leader in the treatment of prostate cancer, the second most commonly diagnosed cancer in men.
Bayer is focused on three scientific areas that have the potential to address unmet needs for patients with cancer, which include targeted radiopharmaceuticals, next-generation immuno-oncology and precision molecular oncology.
Targeted radionuclide therapy (TRT) is a strategic area of focus for Bayer in oncology precision drug development, building on more than 10 years of real-world experience with a targeted alpha therapy for patients with metastatic castration-resistant prostate cancer (mCRPC).
Strategic investments in R&D and platform companies in recent years are further strengthening Bayer’s pipeline. With Vividion’s acquisition of Tavros Therapeutics, Bayer with its chemoproteomics technology platform is working to unlock traditionally undruggable targets with precision small-molecule therapeutics. Through AskBio, a wholly owned subsidiary of Bayer, it is developing a gene therapy as a potential new approach for treating congestive heart failure. Bayer and BlueRock Therapeutics, a wholly owned subsidiary of Bayer are developing an investigational cell therapy based on the surgical implantation of dopamine-generating nerve cell precursors into the brain, said the company."